Candel Therapeutics, Inc. short interest in 2023
In 2023, Candel Therapeutics, Inc.'s disclosed short interest ran from 0.10% of shares outstanding on 13 Jan 2023 to 0.13% on 30 Nov 2023, a change of +0.03 percentage points. The year's high was 0.60% on 31 Jul 2023 and its low 0.08% on 31 Jan 2023, averaging 0.34% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.87 days on 15 Aug 2023. Full history: Candel Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.10% (13 Jan 2023)
- End of year
- 0.13% (30 Nov 2023)
- Change
- +0.03 pp
- High
- 0.60% (31 Jul 2023)
- Low
- 0.08% (31 Jan 2023)
- Average
- 0.34%
- Highest days to cover
- 19.87 (15 Aug 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.10% | 1.00 | |
| 31 Jan 2023 | 0.08% | 1.00 | |
| 15 Feb 2023 | 0.10% | 1.37 | |
| 28 Feb 2023 | 0.10% | 2.17 | |
| 15 Mar 2023 | 0.14% | 2.45 | |
| 31 Mar 2023 | 0.18% | 3.21 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 0.18% | 6.46 | |
| 31 May 2023 | 0.43% | 7.85 | 10-Q filed, results (8-K) |
| 15 Jun 2023 | 0.47% | 6.69 | |
| 30 Jun 2023 | 0.57% | 5.19 | |
| 14 Jul 2023 | 0.55% | 10.09 | |
| 31 Jul 2023 | 0.60% | 8.24 | |
| 15 Aug 2023 | 0.56% | 19.87 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 0.57% | 8.67 | |
| 15 Sep 2023 | 0.55% | 15.54 | |
| 29 Sep 2023 | 0.56% | 4.44 | |
| 13 Oct 2023 | 0.55% | 8.26 | |
| 31 Oct 2023 | 0.24% | 2.33 | |
| 15 Nov 2023 | 0.14% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 0.13% | 1.66 |
See also: Candel Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.